|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Pascal Soriot D.V.M., M.B.A.||CEO & Exec. Director||5,76M||N/D||1959|
|Dr. Aradhana Sarin M.D.||CFO & Exec. Director||4,25M||N/D||1975|
|Mr. Marc Dunoyer||CEO of Alexion & Chief Strategy Officer||2,01M||N/D||1952|
|Ms. Pam P. Cheng||EVP of Operations & Information Technology and Member of External Sustainability Advisory Board||N/D||N/D||1971|
|Mr. Chris Sheldon||Head of Investor Relations||N/D||N/D||N/D|
|Mr. Jeffrey Pott||Chief HR Officer, Gen. Counsel & Member of External Sustainability Advisory Board||N/D||N/D||N/D|
|Ms. Katarina Ageborg||EVP of Sustainability, Chief Compliance Officer & Member of External Sustainability Advisory Board||N/D||N/D||N/D|
|Gonzalo Vina||Head of Global Media Relations||N/D||N/D||N/D|
|Dr. Menelas Pangalos Ph.D.||EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board||N/D||N/D||1967|
|Dr. Ruud Dobber Ph.D.||Exec. Vice-Pres of BioPharmaceuticals Bus. Unit||N/D||N/D||N/D|
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
L'ISS Governance QualityScore di AstraZeneca PLC al 31 luglio 2022 è 7. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 8; diritti degli azionisti: 1; retribuzione: 7.